Atrium Therapeutics raises $50M to fund RNA heart drugs through 2028
What's the deal? Atrium TherapeuticsDealroom has a profile for this one. Try Dealroom →, a San Diego biopharmaceutical company developing RNA therapeutics for the heart, has raised approximately $50 million in a private placement. Investors include Sirenia Capital ManagementDealroom has a profile for this one. Try Dealroom →, AberdeenDealroom has a profile for this one. Try Dealroom → Investments, Montanova, Sessa CapitalDealroom has a profile for this one. Try Dealroom →, and Casdin Capital. The round, priced at-the-market under Nasdaq rules, is expected to close on or about October 9, 2026.
What's the endgame? Atrium is building precision cardiology treatments that deliver RNA therapeutics directly to the heart, aiming to transform care for people with cardiomyopathies. It intends to use the net proceeds, alongside existing cash, to fund its two lead product candidates, other research programs, and general corporate purposes.
Why now? The financing follows the US Food and Drug Administration's clearance of Atrium's Investigational New Drug application for ATR-1072, its first clinical program, targeting PRKAG2 syndrome. The candidate is advancing into the Corventis Phase 1/2 trial.
Under the agreement, Atrium will issue 5,170,384 shares at $7.93 each, plus pre-funded warrants for up to 1,134,930 shares. The company estimates the proceeds, combined with current cash, will fund operations through 2028. Leerink PartnersDealroom has a profile for this one. Try Dealroom → acted as lead placement agent, with CantorDealroom has a profile for this one. Try Dealroom →, Barclays, and Wells Fargo SecuritiesDealroom has a profile for this one. Try Dealroom → as placement agents.
The signal: At $50 million, the round lands in the higher band of comparable deals, a notable raise for a clinical-stage biotech moving its first program into human trials. The backing signals continued institutional appetite for RNA-based precision medicine, even as the funding runway stretches only to 2028 — well before any lead candidate reaches market.
Read more: prnewswire.com
Image credit: Atrium Therapeutics
